Assembly Biosciences (NASDAQ:ASMB) Posts Earnings Results, Beats Expectations By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52, FiscalAI reports. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%.

Assembly Biosciences Stock Up 10.7%

Shares of ASMB stock traded up $2.89 during trading hours on Thursday, hitting $29.95. 728,714 shares of the company’s stock traded hands, compared to its average volume of 148,622. The stock has a market cap of $476.00 million, a PE ratio of -272.25 and a beta of 1.10. The stock’s 50 day simple moving average is $25.77 and its 200 day simple moving average is $27.33. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71.

Institutional Trading of Assembly Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at about $228,000. Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at about $251,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Assembly Biosciences during the third quarter worth about $282,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ASMB. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Guggenheim restated a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences has an average rating of “Moderate Buy” and a consensus target price of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.